INNOVATION MODELS IN THE BIOPHARMACEUTICAL SECTOR - Innovation in the Biopharmaceutical Industry - page 26

DiMasi JA, RW Hansen, HG Grabowski and L Lasagna (1995). Research and development
costs for new drugs by therapeutic category. Pharmacoeconomics , 7, 152.
DiMasi et al. (xxxx). Clinical Development Times for New Drugs Drop 18% Revers-
ing 12 Year Trend, July, Boston . Boston, USA: Tufts Center for the Study of Drug
Development.
Dosi, G, C Freeman, R Nelson, G Silverberg and L Soete (1988). Technical Change and
Economic Theory . London: Francis Pinter.
Dosi, G (1982). Technological paradigms and technological trajectories. Research Policy ,
11, 147-162.
Dosi G (1992). Research on innovation diffusion in economics of innovation — the
case of the pharmaceutical industry. Rivista Internazionale di Scienze Sociali ,3,
219-228.
Epstein RA (2006). Overdose: How Excessive Government Regulation Stifles Pharmaceu-
tical Innovation . Princeton, NJ, USA: Yale University Press.
Ernst and Young (2000) European Life Sciences 2000 . London: Evolution.
Europe Economics (1998). Access to important new medicines; where and why do patients
wait? See http://www.eer.co.uk.
Freeman, C (1982). The Economics of Industrial Innovation . London: Frances Pinter.
George, G, SA Zahra and D Robley-Wood (2002). The effects of business-university
alliances on innovative output and financial performance: a study of publicly traded
biotechnology companies. Journal of Business Venturing , 17, 577-609.
Giaccotto, C, RE Santerre and JA Vernon (2005). Pharmaceutical pricing and R&D growth
rates. Journal of Law and Economics , 48, 195-214.
Golec, J, S Hedge and JA Vernon (2005). Pharmaceutical stock reactions to price constraint
threats and firm-level R&D spending. NBER Working Paper 11229.
Grabowski, H and J Vernon (2000). The distribution of sales revenues from pharmaceutical
innovation. Pharmacoeconomics , 18(Suppl. 1), 21.
Griffin, J (1985). Therapeutic Conservatism in UK Medicine . London: ABPI.
Haigh, J (2004). Developing an Indicator for Market Access Delays in Europe . IMS Global
Consulting at http.//www.imshealth.com.
Henderson, RM and IM Cockburn (1996). Scale Scope and spillovers: determinants of
research productivity in the pharmaceutical industry. RAND Journal of Economics ,
27, 32.
von Hippel, E (1986). Lead users: a source of novel product concepts. Management Science ,
32.
von Hippel, E (1976). Users as innovators. Technology Review , 5, 212.
Jonsson, B and N Wilking (2005). A pan-European Comparison Regarding Patient Access
to Cancer Drugs . Stockholm: Karolinska Institutet and Department of Economics,
Stockholm University.
Kettler, HE (1998). Competition through Innovation, Innovation through Competition .
London: Office of Health Economics, Monograph.
Kettler, HE and S Casper (2000). The Road to Sustainability in the UK and German Biotech-
nology Industries. London: Office of Health Economics, Monograph.